73 results
Page 2 of 4
6-K
EX-99.2
ptpbwo 64u0afc8f
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
F-3
17z1iw wtcjqtmd
10 Nov 21
Shelf registration (foreign)
5:23pm
6-K
EX-99.2
792mykimnv0b fztal
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K/A
EX-99.2
3ujaar
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K/A
EX-99.5
9dwctcw neszt2ejhz
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
EX-99.5
xxfrmro5g2j
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.2
dk5q4g0o
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.2
6qvl5k7d 336
5 Aug 21
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
EX-99.1
qfi2exo4
1 Jun 21
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
6:30am
6-K
EX-99.2
x7wjz0gv1sv4ma
6 May 21
Index to Unaudited Condensed Consolidated Financial Statements
6:03am
6-K
EX-99.1
wn03 tnnnzqg7
22 Apr 21
ObsEva Annual General Meeting 2021
6:31am
6-K
EX-1.1
4t9wm0 7e
5 Mar 21
Current report (foreign)
8:15am
424B5
4dr0n
5 Mar 21
Prospectus supplement for primary offering
7:55am
6-K
EX-99.1
rinr5z9rrnksp
5 Mar 21
ObsEva Announces Year End 2020 Financial Results
7:21am
6-K
EX-1.1
jpurtfoti54gt8x5isg
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
6-K
EX-10.1
2tfnyy5
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
424B5
9gsbu
8 Sep 20
Prospectus supplement for primary offering
7:31am
6-K
94mvi
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.2
gte4r
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am